Taylor Stevenson sits on a bench and smells a bouquet of flowers.

The Stevenson Family’s 2026 Annual Appeal

Meet Taylor Stevenson and his family. Give in Taylor’s honor through FRAXA’s 2026 Annual Appeal to support research toward treatments for Fragile X.

Read More »
Researchers in white lab coats reviewing a computer display beside a microscope.

PDE2 Drug Program Builds on FRAXA-Funded Research

A PDE2 drug program for Fragile X syndrome builds on FRAXA-funded research as Rumi Therapeutics advances RTX-7340 toward clinical development.

Read More »
Dr. Gary Feldman, Principal Investigator for the MRM-3379 Phase 2 clinical trial at the Irvine, California site, standing with an individual with Fragile X syndrome.

Recruiting: Mirum Launches Clinical Trial of MRM-3379 for Fragile X Syndrome

Mirum’s MRM-3379 Phase 2 trial builds on FRAXA-funded PDE4D research and is now enrolling males ages 13–45 with Fragile X syndrome. View eligibility and study sites.

Read More »
Chemical structures of dopamine, istradefylline, and MB-204 with dopamine D2 and adenosine A2A receptors shown below.

FRAXA-DVI Study Finds Promising Results for Marvel Biosciences’ A2A Receptor Drug in Fragile X Model

FRAXA-DVI study finds Marvel Biosciences’ MB-204, an A2A receptor blocker, improved behavior and cognition in a Fragile X mouse model.

Read More »
Researchers Rachid Mazroui, Emeline Lelong, Samer Mohamed Hussein, and Karun Singh collaborate on a FRAXA-funded Fragile X syndrome study using human brain models.

Neurodevelopmental Splicing Defects in Fragile X Syndrome Brain Models

Neurodevelopmental splicing defects in Fragile X syndrome are studied with human brain organoids to identify RNA changes and potential ASO therapies.

Read More »
Close-up illustration of a neuron and synapses symbolizing brain signaling and BK channel activity in Fragile X syndrome

Opening the Gate: BK Channel Modulation as a Promising Treatment Strategy for Fragile X Syndrome

Fragile X syndrome research is opening the door to BK channel therapies that may calm hyperexcitable brain circuits and improve key symptoms.

Read More »
Craig Erickson, MD (left) and Stella Sarraf, PhD (right) on a video call for the Spinogenix SPG601 Fragile X clinical trial.

Spinogenix and FRAXA Advance SPG601 Into Phase 2b Trial for Fragile X Syndrome

Spinogenix and FRAXA are supporting a Phase 2b clinical trial of SPG601 in Fragile X syndrome, building on Phase 2 signals and FDA designations.

Read More »
Two people holding hands, symbolizing a research partnership.

Nospharma Announces Partnership with FRAXA to Test NOS-01 in Pre-Clinical Models of Fragile X

NOS-01 enters the FRAXA Drug Validation Initiative (FRAXA-DVI) for Fragile X mouse-model testing, generating data to guide development decisions.

Read More »
Group photo of Callum Cup IX participants gathered at Millburn High School during the annual charity soccer match supporting Fragile X research.

Callum Cup IX Brings Community Together, Raising $20,000 for Fragile X Research

Callum Cup IX brought the Millburn FC community together, raising $20,000 for the FRAXA Research Foundation in support of Fragile X research.

Read More »

Help Rowan Thrive: Support Fragile X Research

Join the Gale and Kellogg families in supporting Fragile X research through FRAXA. Help Rowan and others thrive by funding life-changing treatments and advancing curative therapies.

Read More »
Laura Cancedda, PhD, principal investigator at the Italian Institute of Technology

Advanced Preclinical Testing of NKCC1 Inhibitors Supporting Phase 2 Trials in Fragile X

The project evaluates a next-generation NKCC1 inhibitor, studying its safety and effects on brain signaling to determine its potential to progress into Phase 2 clinical trials.

Read More »
The Hye Young Lee Lab at UT Health San Antonio – a dynamic team leading cutting-edge gene therapy research for Fragile X syndrome using next-generation mRNA delivery systems.

Gene Therapeutic Development for Fragile X Syndrome

Dr. Lee’s team is testing novel gene editing therapies for Fragile X, aiming to repair FMR1 and restore the missing protein — a promising new strategy which is targeted and reversible.

Read More »
FRAXA Q&A Webinar with Dr. Elizabeth Berry-Kravis on the Harmony RECONNECT Trial

Fragile X Research Q&A: Dr. Berry-Kravis on the RECONNECT Trial

Fragile X Research Q&A with Dr. Berry-Kravis on RECONNECT results, placebo effects, outcome measures, methylation, and research directions for families.

Read More »
Dr. Joel Richter and Dr. Sneha Shah in their UMass Chan Medical School lab researching ASO therapy for Fragile X syndrome.

ASO Rescue of FMR1 Mis-Splicing in Neurons and Mitigation of Fragile X Deficits

A new FRAXA grant funds UMass Chan researchers using ASOs in neurons and organoids to correct FMR1 mis-splicing and restore critical FMRP protein.

Read More »
#teamwally shares a joyful outdoor moment supporting Fragile X awareness as the kids explore a steering wheel together

Cognitive Rigidity: a Hallmark of Fragile X and Autism

Cognitive rigidity shapes daily life in Fragile X, driving anxiety and repetitive behaviors. Learn its impact on treatment and independence.

Read More »
Jeannie Lee, MD, PhD and Chloe Chen, PhD

Modeling R-Loop Therapy for Fragile X Syndrome in Patient-Derived Brain Organoids

Fragile X syndrome researchers model R-loop therapy in patient-derived brain organoids to restore FMR1, accelerating a curative approach supported by FRAXA.

Read More »
Marine Anais Krzisch, PhD

Role of Microglia in Fragile X Syndrome

Learn how Dr. Marine Anais Krzisch’s $35K FRAXA and ASF-funded project uses human iPSC microglia models to uncover pathways for Fragile X syndrome treatment.

Read More »
Dr. Thomas Maurin and Dr. Barbara Bardoni, Fragile X researchers and co-authors of a 2025 review on PDE inhibitors published in Cell Reports Medicine.

Fragile X and PDE Inhibitors: A Promising Path Forward for Brain Disorders

Fragile X syndrome research shows PDE inhibitors may improve brain function and behavior, with promise for related neurodevelopmental disorders.

Read More »

Urgent Action Needed: Help Secure NIH Funding for Fragile X Research

NIH funding delays threaten Fragile X research, putting critical studies and future treatments at risk. Help us urge Congress and the NIH to act now.

Read More »

Combining Gene Reactivation with Controlled Sound Exposure to Treat Fragile X Syndrome

The team combined gene reactivation with noninvasive acoustic stimulation in a mouse model as an approach to treating Fragile X syndrome.

Read More »

FRAXA-Funded Research Explores ISRIB as a Potential Treatment for Fragile X

ISRIB for Fragile X syndrome is being studied as a potential treatment to restore brain function and social behavior. Researchers investigate its effects.

Read More »

Clinical Study of Non-Invasive EEG for Children Ages 2-7

Dr. Carol Wilkinson, MD PhD at Boston Children’s Hospital recruited children ages 2-7 years with Fragile X syndrome to participate in a study of EEG.

Read More »

Callum Cup VIII Scores $19,400 for Fragile X Research – A Milestone Event

Callum Cup VIII, Millburn FC’s annual charity match, scored big with $19,400 raised for Fragile X research, bringing total funds to $148,000!

Read More »

Marvel Biosciences Partners with FRAXA to Test MB204 for Fragile X Syndrome

Marvel Biosciences and FRAXA Research Foundation are collaborating to test MB204, a promising new treatment for Fragile X which targets adenosine receptors.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (42)